0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: A 18FDG PET/CT study in more than 6,000 patients

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The clinical significance of incidental thyroid abnormalities discovered in 18F-FDG PET/CT (FDG PET/CT) studies remains controversial. The objective of this large retrospective study was to a) determine the prevalence of focal FDG thyroid uptake on whole body FDG PET/CT studies performed for non-thyroid cancers and b) to test whether intense focal FDG thyroid uptake is associated with malignancy.

          Methods

          A total of 11,921 FDG PET/CT studies in 6,216 patients performed at our institution between 01/2012 and 12/2014 were analyzed. We retrospectively reviewed the medical records of these patients. Eight hundred forty five/6,216 patients (13.6%) had a thyroid incidentaloma based on the clinical 18FDG PET/CT report. One hundred sixty/845 (18.9%) of these underwent ultrasound and 98 of these (61.3%) had a fine needle aspiration (FNA). Twenty-six of these 98 (26.5%) patients underwent thyroidectomy. Thyroid lesion and background SUV's for each patient were measured upon review of the 18FDG PET/CT study. We measured SUVmax, thyroid to background ( T L T B G ), thyroid to blood pool ( T L B P ) and thyroid to liver ( T L L ) ratios in benign and malignant lesions. Receiver operating curves (ROC) were calculated to determine optimal cut off values between malignant and benign lesions

          Results

          Twenty-one of the 98 patients who underwent FNA biopsy or thyroidectomy had malignant disease (21.4%). Malignant lesions had significantly higher thyroid lesion SUVmax, T L T B G , T L B P , and T L L than benign nodules. The ROC derived cut off ratio T L T B G of >2.0 differentiated benign from malignant lesions best with a specificity and sensitivity of 0.76 and 0.88, respectively.

          Conclusions

          The incidence of malignancy in biopsied focal hypermetabolic thyroid lesions is 21.4%. Lesions on FDG PET/CT studies, exhibiting a ratio T L T B G > 2.0 , warrant further work up with ultrasound and FNA to exclude malignancy.

          Related collections

          Author and article information

          Journal
          8201017
          6186
          Nucl Med Commun
          Nucl Med Commun
          Nuclear medicine communications
          0143-3636
          1473-5628
          14 September 2016
          December 2016
          01 December 2017
          : 37
          : 12
          : 1290-1296
          Affiliations
          [1 ]Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, USA
          [2 ]Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, USA
          [3 ]Section of Endocrine Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, USA
          [4 ]Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
          Author notes

          Author Contact Information:

          Martin J Barrio, MS, Ahmanson Translation Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-7370, USA, mbarrio@ 123456iu.edu

          Johannes Czernin, MD, Ahmanson Translation Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-7370, USA, jczernin@ 123456mednet.ucla.edu

          Michael Yeh, MD, Department of Surgery, Section of Endocrine Surgery, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-7370, USA, MYeh@ 123456mednet.ucla.edu

          Miguel Fernando Palma Diaz, MD, Department of Pathology and Laboratory Science, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-7370, USA, FPalmaDiaz@ 123456mednet.ucla.edu

          Christiaan Schiepers, MD/PhD, Ahmanson Translation Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-7370, USA, cschiepers@ 123456mednet.ucla.edu

          Pawan Gupta, MD, Ahmanson Translation Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-7370, USA, PawanGupta@ 123456mednet.ucla.edu

          Martin Allen-Auerbach, MD, Ahmanson Translation Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095-7370, USA, mauerbach@ 123456mednet.ucla.edu

          Corresponding Author: Ken Herrmann, MD, Ahmanson Translation Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, CHS AR-255, Los Angeles, CA 90095-7370, USA, kherrmann@ 123456mednet.ucla.edu
          Article
          PMC5077695 PMC5077695 5077695 nihpa813756
          10.1097/MNM.0000000000000592
          5077695
          27612034
          e87ea036-190e-4c7b-8eea-a8d3cbd3c446
          History
          Categories
          Article

          Thyroid,Incidental findings,PET,FDG
          Thyroid, Incidental findings, PET, FDG

          Comments

          Comment on this article